Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
07/05/2026 06:55
May 7 (Reuters) - argenx SE ARGX.BR: ARGENX Q1 TOTAL OPERATING INCOME USD 1,313 MILLION Q1 EPS USD 5.52 Q1 BASIC EPS USD 5.9 Q1 NET INCOME USD 366 MILLION Q1 OPERATING EXPENSES USD -919 MILLION PDUFA TARGET ACTION DATE FOR ANTI-ACHR ANTIBODY NEGATIVE GMG IS MAY 10, 2026 Q1 COST OF SALES USD -121 MILLION VERSUS USD -81 MILLION IN Q1 2025 Q1 PROFIT USD 366 MILLION VERSUS USD 169 MILLION IN Q1 2025 ADIMANEBART CMS REGISTRATIONAL STUDY ON TRACK TO START IN Q3 OF 2026 PHASE 2 STUDY OF ARGX-121 IN IGA NEPHROPATHY (IGAN) EXPECTED TO START IN 2026 THREE NEW FIRST-IN-CLASS MOLECULES ON TRACK TO ENTER PHASE 1 IN 2026 VYVGART SC AUTOINJECTOR EXPECTED TO LAUNCH IN 2027 FOR ALL APPROVED INDICATIONS Source text: nGNEbTYfS5 Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on argenx SE
See all newsBrief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles
Brief: Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader Vyvgart Use Across MG And CIDP